Disclosed are MEK inhibitors having the Formula I or a pharmaceutically acceptable salt thereof, wherein: R 1 is Cl or F; R 3 is H, Me, Et, OH, MeO-, EtO-, HOCH 2 CH 2 O-, HOCH 2 C(Me) 2 O-, (S)-MeCH(OH)CH 2 O-, (R)-HOCH 2 CH(OH)CH 2 O-, cyclopropyl-CH 2 O-, HOCH 2 CH 2 -, R 7 is cyclopropyl-CH 2 - or C 1 -C 4 alkyl, wherein said alkyl is optionally substituted with one or more F; R 8 is Br, I or SMe; and R 9 is CH 3 , CH 2 F, CHF 2 , CF 3 , F or Cl, useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions.